Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06641076 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Study acronym: IZAR-1
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Feb 4, 2027 to May 28, 2026 Eligibility criteria expanded, about 12 words · Secondary endpoints: details revised at 1 of 6 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 6 entries
  2. Site details revised at 1 of 182 sitesv14
  3. Re-verified, no change to tracked fieldsv13
  4. Trial sites expanded: 169 → 182 locationsv12
  5. Study sites: 168 to 169v11
Show 9 earlier versionsHide 9 earlier versions
  1. 2 versions Re-verified since Mar 25, 2026, no change to tracked fieldsv9-v10
  2. Trial status: Recruiting to Active, Not Recruiting Primary and study completion dates: Jan 15, 2027 to Feb 4, 2027 · Site details revised at 168 of 168 sitesv8 Show 2 more changesShow less
    • Primary and study completion dates: Jan 15, 2027 to Feb 4, 2027
    • Site details revised at 168 of 168 sites
  3. Study sites: 167 to 168 Eligibility criteria shortened, about 2 wordsv7 Show 1 more changeShow less
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 163 to 167v6
  5. Study sites: 162 to 163v5
  6. Study sites: 26 to 162v4
  7. Study sites: 2 to 26v3
  8. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2v2 Show 1 more changeShow less
    • Study sites: 0 to 2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
Trial Details
NCT Number NCT06641076
Lead Sponsor MoonLake Immunotherapeutics AG
Conditions Arthritis, Psoriatic
Enrollment 960 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov